YES1 Amplification

CI-VAR-00000254Explore in graph →CIViC 5000

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR Mutation AND YES1 Amplification	Afatinib	Predictive	D	Supports Resistance	3	rejected	EID12094 A transposon mutagenesis screen for resistance to a second-generation TKI afatinib was performed in EGFR-TKI sensitive PC9 lung adenocarcinoma cell line that harbours exon 19 EGFR deletion. YES1 was f… (full text at CIViC) PMID 29875142 · Fan et al., 2018 · Open in CIViC	civic
Lung Small Cell Carcinoma1
YES1 Overexpression OR YES1 Amplification	CH6953755 + DasatinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID12556 In preclinical small cell lung carcinoma (SCLC) models with YES1 amplification or high expression, treatment with the YES1 inhibitor CH6953755 (30 mg/kg, q2d) or dasatinib (45 mg/kg daily) produced ma…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Breast Neoplasm1
ERBB2 Amplification AND YES1 Amplification	Neratinib	Predictive	D	Supports Resistance	3	submitted	EID12095 Neratinib-resistant cell lines were established by stepwise escalation method and high concentration method in breast cancer cell line BT-474 and lung cancer cell line H2170 with HER2 amplification. E… (full text at CIViC) PMID 31856375 · Takeda et al., 2020 · Open in CIViC	civic

Malignant Lung Neoplasm1
ERBB2 Amplification AND YES1 Amplification	Neratinib	Predictive	D	Supports Resistance	3	submitted	EID12096 Neratinib-resistant cell lines were established by stepwise escalation method and high concentration method in breast cancer cell line BT-474 and lung cancer cell line H2170 with HER2 amplification. E… (full text at CIViC) PMID 31856375 · Takeda et al., 2020 · Open in CIViC	civic